Peek Behind the Paper: real-world data concerning the efficacy of osimertinib in a subset of NSCLC patients

In this feature, we peek behind the paper with contributing study author Filippo de Marinis (European Institute of Oncology, Milan, Italy): the ASTRIS study. Please could you introduce yourself and your research focus? I am the Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO; Milan, Italy). My clinical research focuses on thoracic oncology. Why was the ASTRIS study initiated? At the time the ASTRIS study was proposed, there was minimal clinical data — and very little real-world data (RWD) — concerning patients with T790M-mutant, epidermal growth factor receptor (EGFR) non-small-cell lung cancer (NSCLC), following their...